Press release: Sequana Medical announces 2024 Full Year Results and 2025 Outlook
Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® –…
TREATMENT.COM AI INC. EXTENDS TERM OF MARKETING SERVICES PROVIDED BY I2I MARKETING GROUP
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR…
ACTG Presents Data from Mpox Study STOMP at CROI
LOS ANGELES, March 12, 2025 (GLOBE NEWSWIRE) -- ACTG, a global clinical…
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on March 13, 2025
Nyxoah to Release Fourth Quarter and Financial Year 2024 Financial Results on…
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
SAN FRANCISCO, March 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”)…
Data of InnoCare’s ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD
BEIJING--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing…
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor…
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
ROCKVILLE, Md. and SUZHOU, China, March 05, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader…
EMFACE Surpasses 1 Million Treatments, Becoming the Fastest-Growing Non-Invasive Facial Lifting Procedure
PRAGUE, March 5, 2025 /PRNewswire/ -- EMFACE, the revolutionary non-invasive facial treatment, has…